Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: baggo who wrote (1214)	3/6/1998 6:05:00 PM
From: JanyBlueEyes	Read Replies (2) \| Respond to of 5736

Doctors are much more willing to perform a test/procedure when the side effects/complications are nil. IMO that statment is correct. The numbers given by CCSI regarding the size of market did not take into account any increased frequency of testing that would occur simply because of the safety, cost-effectiveness and ease of use of the device. Nor did it take into account the "emerging Home Healthcare market". From techstocks.com - CONFERENCE CALL TRANSCRIPT 9/17/97: Although the Company and its potential marketing partners believe that future frequency of testing may increase to the extent the non-invasive device may revolutionize the current standard patient care for hyperbilirubinemia and may introduce non-invasive monitoring tests into the emerging Home Healthcare Care market, our conservative assumptions are not based on any increased frequency of bilirubin testing in hospitals and pediatrician offices, nor do they reflect parents' use in the home or a visiting nurse carrying one of the Company's non-invasive monitoring devices.......